<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39353188</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2371-4379</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JMIR diabetes</Title><ISOAbbreviation>JMIR Diabetes</ISOAbbreviation></Journal><ArticleTitle>Impact of Telemedicine Versus In-Person Pediatric Outpatient Type 1 Diabetes Visits on Immediate Glycemic Control: Retrospective Chart Review.</ArticleTitle><Pagination><StartPage>e58579</StartPage><MedlinePgn>e58579</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e58579</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/58579</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Children and adolescents with type 1 diabetes require frequent outpatient evaluation to assess glucose trends, modify insulin doses, and screen for comorbidities. Continuous glucose monitoring (CGM) provides a detailed glycemic control assessment. Telemedicine has been increasingly used since the COVID-19 pandemic.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate CGM profile parameter improvement immediately following pediatric outpatient diabetes visits and determine if visit modality impacted these metrics, completion of screening laboratory tests, or diabetic emergency occurrence.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A dual-center retrospective review of medical records assessed the CGM metrics time in range and glucose management indicator for pediatric outpatient diabetes visits during 2021. Baseline values were compared with those at 2 and 4 weeks post visit. Rates of completion of screening laboratory tests and diabetic emergencies following visits were determined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 269 outpatient visits (41.2% telemedicine) were included. Mean time in range increased by 1.63% and 1.35% at 2 and 4 weeks post visit (P=.003 and .01, respectively). Mean glucose management indicator decreased by 0.07% and 0.06% at 2 and 4 weeks post visit (P=.003 and .02, respectively). These improvements in time in range and glucose management indicator were seen across both telemedicine visits and in-person visits without a significant difference. However, patients seen in person were 2.69 times more likely to complete screening laboratory tests (P=.03). Diabetic emergencies occurred too infrequently to analyze.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings demonstrate an immediate improvement in CGM metrics following outpatient visits, regardless of modality. While statistically significant, the magnitude of these changes was small; hence, multiple visits over time would be required to achieve clinically relevant improvement. However, completion of screening laboratory tests was found to be more likely after visits occurring in person. Therefore, we suggest a hybrid approach that allows patient convenience with telemedicine but also incorporates periodic in-person assessment.</AbstractText><CopyrightInformation>©Christopher Ferber, Steven D Mittelman, Tannaz Moin, Holly Wilhalme, Rebecca Hicks. Originally published in JMIR Diabetes (https://diabetes.jmir.org), 01.10.2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferber</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0677-8740</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology, University of California Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Endocrine and Diabetes Center, Miller Children's and Women's Hospital Long Beach, Long Beach, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mittelman</LastName><ForeName>Steven D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0003-2867-1298</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology, University of California Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Children's Discovery and Innovation Institute, UCLA Mattel Children's Hospital, David Geffen School of Medicine, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moin</LastName><ForeName>Tannaz</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5035-6641</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Metabolism, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HSR&amp;D Center for the Study of Healthcare Innovation, Implementation &amp; Policy, VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilhalme</LastName><ForeName>Holly</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9908-6219</Identifier><AffiliationInfo><Affiliation>Department of Medicine Statistics Core, Division of General Internal Medicine and Health Services Research, University of California Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hicks</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3060-971X</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology, University of California Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Endocrine and Diabetes Center, Miller Children's and Women's Hospital Long Beach, Long Beach, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Diabetes</MedlineTA><NlmUniqueID>101719410</NlmUniqueID><ISSNLinking>2371-4379</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">continuous glucose monitoring</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">glucose management indicator</Keyword><Keyword MajorTopicYN="N">pediatrics</Keyword><Keyword MajorTopicYN="N">screening labs</Keyword><Keyword MajorTopicYN="N">telemedicine</Keyword><Keyword MajorTopicYN="N">time in range</Keyword><Keyword MajorTopicYN="N">type 1 diabetes</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>3</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>16</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39353188</ArticleId><ArticleId IdType="pmc">PMC11480684</ArticleId><ArticleId IdType="doi">10.2196/58579</ArticleId><ArticleId IdType="pii">v9i1e58579</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):481–497. doi: 10.1016/j.ecl.2010.05.011. 
 
S0889-8529(10)00043-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ecl.2010.05.011</ArticleId><ArticleId IdType="pmc">PMC2925303</ArticleId><ArticleId IdType="pubmed">20723815</ArticleId></ArticleIdList></Reference><Reference><Citation>ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association  14. Children and adolescents: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S230–S253. doi: 10.2337/dc23-S014. 
 
148046</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc23-S014</ArticleId><ArticleId IdType="pmc">PMC9810473</ArticleId><ArticleId IdType="pubmed">36507640</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, Wolfsdorf JI, Schatz D. Type 1 diabetes in children and adolescents: a position statement by the American diabetes association. Diabetes Care. 2018;41(9):2026–2044. doi: 10.2337/dci18-0023. 
 
dci18-0023</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dci18-0023</ArticleId><ArticleId IdType="pmc">PMC6105320</ArticleId><ArticleId IdType="pubmed">30093549</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller KM, Hermann J, Foster N, Hofer SE, Rickels MR, Danne T, Clements MA, Lilienthal E, Maahs DM, Holl RW, T1D ExchangeDPV Registries  Longitudinal changes in continuous glucose monitoring use among individuals with type 1 diabetes: international comparison in the German and Austrian DPV and U.S. T1D exchange registries. Diabetes Care. 2020;43(1):e1–e2. doi: 10.2337/dc19-1214. 
 
dc19-1214</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc19-1214</ArticleId><ArticleId IdType="pmc">PMC7881298</ArticleId><ArticleId IdType="pubmed">31672703</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther. 2017;19(S3):S25–S37. doi: 10.1089/dia.2017.0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dia.2017.0035</ArticleId><ArticleId IdType="pmc">PMC5467105</ArticleId><ArticleId IdType="pubmed">28585879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona-Hernandez R, Schwandt A, Alkandari H, Bratke H, Chobot A, Coles N, Corathers S, Goksen D, Goss P, Imane Z, Nagl K, O'Riordan SMP, Jefferies C, SWEET Study Group Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the international pediatric registry sweet. Diabetes Care. 2021;44(5):1176–1184. doi: 10.2337/dc20-1674.dc20-1674</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-1674</ArticleId><ArticleId IdType="pubmed">33653821</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer-Davis E, Davis C, Saadine J, D'Agostino RB, Dabelea D, Dolan L, Garg S, Lawrence JM, Pihoker C, Rodriguez BL, Klein BE, Klein R, SEARCH for Diabetes in Youth Study Group  Diabetic retinopathy in the search for diabetes in youth cohort: a pilot study. Diabet Med. 2012;29(9):1148–1152. doi: 10.1111/j.1464-5491.2012.03591.x. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-5491.2012.03591.x</ArticleId><ArticleId IdType="pmc">PMC4495729</ArticleId><ArticleId IdType="pubmed">22269205</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan DM, DCCT/EDIC Research Group  The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9–16. doi: 10.2337/dc13-2112. 
 
37/1/9</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-2112</ArticleId><ArticleId IdType="pmc">PMC3867999</ArticleId><ArticleId IdType="pubmed">24356592</ArticleId></ArticleIdList></Reference><Reference><Citation>The Diabetes Control and Complications Trial Research Group The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–983. doi: 10.2337/diabetes.44.8.968.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.44.8.968</ArticleId><ArticleId IdType="pubmed">7622004</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Gadi I, Menon S, Lyons SK, DeSalvo DJ. Beyond A1C: a practical approach to interpreting and optimizing continuous glucose data in youth. Diabetes Spectr. 2021;34(2):139–148. doi: 10.2337/ds20-0095. 
 
DS200095</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/ds20-0095</ArticleId><ArticleId IdType="pmc">PMC8178721</ArticleId><ArticleId IdType="pubmed">34149254</ArticleId></ArticleIdList></Reference><Reference><Citation>Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–1603. doi: 10.2337/dci19-0028. 
 
dci19-0028</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dci19-0028</ArticleId><ArticleId IdType="pmc">PMC6973648</ArticleId><ArticleId IdType="pubmed">31177185</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin G. Type 1 diabetes mellitus and celiac disease: distinct autoimmune disorders that share common pathogenic mechanisms. Horm Res Paediatr. 2019;92(5):285–292. doi: 10.1159/000503142. doi: 10.1159/000503142.000503142</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000503142</ArticleId><ArticleId IdType="doi">10.1159/000503142</ArticleId><ArticleId IdType="pubmed">31593953</ArticleId></ArticleIdList></Reference><Reference><Citation>Frommer L, Kahaly GJ. Type 1 diabetes and autoimmune thyroid disease-the genetic link. Front Endocrinol (Lausanne) 2021;12:618213. doi: 10.3389/fendo.2021.618213. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.618213</ArticleId><ArticleId IdType="pmc">PMC7988207</ArticleId><ArticleId IdType="pubmed">33776915</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskar S, Bradley S, Chattu VK, Adisesh A, Nurtazina A, Kyrykbayeva S, Sakhamuri S, Yaya S, Sunil T, Thomas P, Mucci V, Moguilner S, Israel-Korn S, Alacapa J, Mishra A, Pandya S, Schroeder S, Atreja A, Banach M, Ray D. Telemedicine across the globe-position paper from the COVID-19 pandemic health system resilience program (REPROGRAM) international consortium (Part 1) Front Public Health. 2020;8:556720. doi: 10.3389/fpubh.2020.556720. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.556720</ArticleId><ArticleId IdType="pmc">PMC7596287</ArticleId><ArticleId IdType="pubmed">33178656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM, Carlson E, Albanese-O'Neill A, Demeterco-Berggren C, Corathers SD, Vendrame F, Weinstock RS, Prahalad P, Alonso GT, Kamboj M, DeSalvo DJ, Malik FS, Izquierdo R, Ebekozien O. Adoption of telemedicine for type 1 diabetes care during the COVID-19 pandemic. Diabetes Technol Ther. 2021;23(9):642–651. doi: 10.1089/dia.2021.0080. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dia.2021.0080</ArticleId><ArticleId IdType="pmc">PMC8501471</ArticleId><ArticleId IdType="pubmed">33851873</ArticleId></ArticleIdList></Reference><Reference><Citation>Faruque LI, Wiebe N, Ehteshami-Afshar A, Liu Y, Dianati-Maleki N, Hemmelgarn BR, Manns BJ, Tonelli M, Alberta Kidney Disease Network  Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials. CMAJ. 2017;189(9):E341–E364. doi: 10.1503/cmaj.150885. 
 
cmaj.150885</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.150885</ArticleId><ArticleId IdType="pmc">PMC5334006</ArticleId><ArticleId IdType="pubmed">27799615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassi M, Strati MF, Parodi S, Lightwood S, Rebora C, Rizza F, d'Annunzio G, Minuto N, Maghnie M. Patient satisfaction of telemedicine in pediatric and young adult Type 1 diabetes patients during Covid-19 pandemic. Front Public Health. 2022;10:857561. doi: 10.3389/fpubh.2022.857561. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.857561</ArticleId><ArticleId IdType="pmc">PMC8980324</ArticleId><ArticleId IdType="pubmed">35392480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman FR, Halvorson M, Carpenter S. Association between diabetes control and visits to a multidisciplinary pediatric diabetes clinic. Pediatrics. 1999;103(5 Pt 1):948–951. doi: 10.1542/peds.103.5.948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.103.5.948</ArticleId><ArticleId IdType="pubmed">10224170</ArticleId></ArticleIdList></Reference><Reference><Citation>Renders CM, Valk GD, Griffin SJ, Wagner EH, Eijk Van JT, Assendelft WJ. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care. 2001;24(10):1821–1833. doi: 10.2337/diacare.24.10.1821.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.24.10.1821</ArticleId><ArticleId IdType="pubmed">11574449</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong A, Amat MJ, Anderson TS, Shafiq U, Sternberg SB, Salant T, Fernandez L, Schiff GD, Aronson MD, Benneyan JC, Singer SJ, Phillips RS. Completion of recommended tests and referrals in telehealth vs in-person visits. JAMA Netw Open. 2023;6(11):e2343417. doi: 10.1001/jamanetworkopen.2023.43417. 
 
2811870</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.43417</ArticleId><ArticleId IdType="pmc">PMC10652149</ArticleId><ArticleId IdType="pubmed">37966837</ArticleId></ArticleIdList></Reference><Reference><Citation>Baughman D, Zain A, Waheed A. Patient adherence to hemoglobin A1c testing recommendations in telemedicine and in-office cohorts during COVID-19. JAMA Netw Open. 2021;4(9):e2127779. doi: 10.1001/jamanetworkopen.2021.27779. 
 
2784597</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.27779</ArticleId><ArticleId IdType="pmc">PMC8485170</ArticleId><ArticleId IdType="pubmed">34591108</ArticleId></ArticleIdList></Reference><Reference><Citation>DeSalvo DJ, Noor N, Xie C, Corathers SD, Majidi S, McDonough RJ, Polsky S, Izquierdo R, Rioles N, Weinstock R, Obrynba K, Roberts A, Vendrame F, Sanchez J, Ebekozien O. Patient demographics and clinical outcomes among type 1 diabetes patients using continuous glucose monitors: data from T1D exchange real-world observational study. J Diabetes Sci Technol. 2023;17(2):322–328. doi: 10.1177/19322968211049783. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/19322968211049783</ArticleId><ArticleId IdType="pmc">PMC10012384</ArticleId><ArticleId IdType="pubmed">34632823</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A. In type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med. 2008;25(3):326–332. doi: 10.1111/j.1464-5491.2007.02365.x.DME2365</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-5491.2007.02365.x</ArticleId><ArticleId IdType="pubmed">18307459</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>